Business & Regulation Business Practice, Biosimilars

Enter the Humira Biosimilars

Humira biosimilars finally launch on the US market

Stephanie Sutton | 07/14/2023 | 2 min read | News

July 2023 is a significant one for biosimilars in the US. As of July 1, more biosimilar versions of Humira will be available and the competition will be heating up. The first Humira biosimilar launched in January 2023 – Amgen’s Amjevita (adalimumab-atto), which received FDA approval in 2016 – but some of the new arrivals have come armed for the fight.

Included in the July launches is Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), which was deemed by the FDA to be therapeutically interchangeable with Humira back in 2021. It is the only Humira biosimilar to have the interchangeability designation.

“The process of bringing biosimilar versions of Humira to the market in the US has involved several factors that have contributed to the time it took for patients to gain access including complex regulatory pathways, exclusive patent protection, and market dynamics,” explains Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim. “Our license period for Cyltezo began on July 1, 2023, which places us among the first alternative biosimilar treatment options.”

Cyltezo’s interchangeability designation was supported by the phase III randomized VOLTAIRE-X trial, which studied the effects of multiple switches between Humira and Cyltezo. Pagnotta says, “A biosimilar with an interchangeable designation can be auto-substituted for the reference product by a pharmacist. Individual state laws control how and whether providers and patients must be notified. Pharmacist-mediated auto-substitution could mean fewer administrative hurdles, which can potentially help patients get their medications faster than they would get non-interchangeable biosimilars.”

The drug is also being launched with a pen autoinjector, features a one-button, three-step activation, with 100 percent drug visibility and a protected needle.

However, other biosimilars manufacturers are reportedly taking steps to obtain the interchangeability designation, so we may see the competition intensifying further in the marketplace.

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Business & Regulation Business Practice, Biosimilars

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.